指南与共识消化系统肿瘤

局部晚期直肠癌的管理:ASCO指南

Management of Locally Advanced Rectal Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2024-08-08

指南涵盖MRI评估后TNT、化疗时机、CRT与短程放疗选择、非手术治疗及免疫治疗等推荐。

要点

  • 微卫星稳定或错配修复完整的局部晚期直肠癌,肿瘤位于低位直肠和/或局部和/或远处转移风险较高者,应首选全程新辅助治疗(TNT)作为初始治疗。
  • 适合TNT者化疗首选在放疗后给予,新辅助长程放化疗优于短程放疗,但短程放疗也可作为可选方案。
  • 新辅助治疗后临床完全缓解者可讨论非手术治疗替代全直肠系膜切除术;微卫星高度不稳定或错配修复缺陷者推荐免疫治疗。

核心结论

  • ASCO发布局部晚期直肠癌管理指南,基于系统评价与专家组非正式共识形成循证推荐。

研究设计与样本

  • 系统评价2013年至2023年发表的文献,纳入系统评价、II期和III期随机对照试验及观察性研究。

主要发现

  • 微卫星稳定或错配修复完整的局部晚期直肠癌患者,经磁共振成像评估后,肿瘤位于低位直肠和/或局部和/或远处转移风险较高者,应首选全程新辅助治疗(TNT;即放化疗[CRT]和化疗)作为初始治疗。
  • 无高危因素的患者可根据缓解程度讨论化疗联合选择性CRT、TNT、或新辅助长程CRT或短程放疗。
  • 适合TNT的患者,化疗首选在放疗后给予,新辅助长程CRT优于短程放疗(RT),但短程RT根据情况也可作为可行治疗选择。
  • 对新辅助治疗达到临床完全缓解的患者,可讨论非手术治疗作为全直肠系膜切除术的替代方案。
  • 肿瘤为微卫星高度不稳定或错配修复缺陷的患者,推荐免疫治疗。

关键数值与推荐

  • 微卫星稳定或错配修复完整的局部晚期直肠癌,肿瘤位于低位直肠和/或局部和/或远处转移风险较高者,应首选TNT作为初始治疗。
  • 适合TNT者化疗首选在放疗后给予,新辅助长程CRT优于短程RT,但短程RT根据情况也可作为可行治疗选择。
  • 新辅助治疗后临床完全缓解者可讨论非手术治疗替代全直肠系膜切除术。
  • 微卫星高度不稳定或错配修复缺陷者推荐免疫治疗。

临床怎么用

  • 临床医生治疗局部晚期直肠癌患者时应参照本指南的循证推荐。
  • 指南供自愿使用,应结合独立专业判断,可能不适用于所有患者、干预措施、疾病或疾病分期。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual. ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.Clinical Practice Guidelines and other guidance ("Guidance") provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by providers and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and 2 (online only) for more.PURPOSETo provide evidence-based guidance for clinicians who treat patients with locally advanced rectal cancer.METHODSA systematic review of the literature published from 2013 to 2023 was conducted to identify relevant systematic reviews, phase II and III randomized controlled trials (RCTs), and observational studies where applicable.RESULTSTwelve RCTs, two systematic reviews, and one nonrandomized study met the inclusion criteria for this systematic review. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.RECOMMENDATIONSFollowing assessment with magnetic resonance imaging, for patients with microsatellite stable or proficient mismatch repair locally advanced rectal cancer, total neoadjuvant therapy (TNT; ie chemoradiation [CRT] and chemotherapy) should be offered as initial treatment for patients with tumors located in the lower rectum and/or patients who are at higher risk for local and/or distant metastases. Patients without higher-risk factors may discuss chemotherapy with selective CRT depending on extent of response, TNT, or neoadjuvant long-course CRT or short-course radiation. For patients who are candidates for TNT, the preferred timing for chemotherapy is after radiation, and neoadjuvant long-course CRT is preferred over short-course radiation therapy (RT), however short-course RT may also be a viable treatment option depending on circumstances. Nonoperative management may be discussed as an alternative to total mesorectal excision for patients who have a clinical complete response to neoadjuvant therapy. For patients whose tumors are microsatellite instability-high or mismatch repair deficient, immunotherapy is recommended.Additional information is available at http://www.asco.org/gastrointestinal-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Scott AJ, Kennedy EB, Berlin J, et al. Management of Locally Advanced Rectal Cancer: ASCO Guideline. J Clin Oncol. 2024. PMID: 39116386. doi:10.1200/JCO.24.01160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。